Lexaria extends pharmaceutical partnership through december 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
April 29, 2026 9:10 AM EDTKELOWNA, BC / ACCESS Newswire / April 29, 2026 / Lexaria Bioscience Corp. (NASDAQ: LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH technology in a pre-clinical setting.
The original agreement has been successfully extended through December 31, 2026, to accommodate time required for PharmaCO's receipt and review of Lexaria's 2026... More
